Discover
JNJ-64304500 / J&JJNJ-64304500: NME filing in US for Crohn's disease between 2020-2023 (J&J) - Jan 22, 2020 - Pipeline Update: Regulatory submission in EU for Crohn's disease between 2020-2023 [Screenshot]
Tremfya (guselkumab) / J&JTremfya: Data from P2/3 GALAXI trial (NCT03466411) for Crohn’s disease in 2020 (J&J) - Jan 22, 2020 - Key 2020 Events [Screenshot]
Skyrizi (risankizumab) / AbbVie, Boehringer IngelheimA Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease Who Responded to Induction Treatment in M16-006 or M15-991; or Completed M15-989 (clinicaltrials.gov) - Jan 21, 2020 - P3; N=1250; Recruiting; Sponsor: AbbVie; N=912 --> 1250
Stelara (ustekinumab) / J&JNICE rejects Janssen’s Stelara on cost efficiency grounds (PharmaTimes) - Jan 22, 2020 - "The National Institute for Health and Care Excellence (NICE) has released a draft guidance not recommending Janssen’s Stelara (ustekinumab) for moderately to severely active ulcerative colitis in adults....NICE said that it already recommends several treatment options...The annual treatment costs are £14,482 in the induction year, and £9,304 per year for maintenance treatment, but the company has agreed a confidential pricing arrangement for the drug with the Commercial Medicines Unit."
Remicade (infliximab) / Mitsubishi Tanabe, J&JRemicade ex-US sales estimate: $400M in 2019; Remicade ex-US sales projection: $300M in 2020 and $5M in 2025 (Cowen & Co) - Jan 21, 2020 - A subscription to Thomson ONE is required to gain full access to report 68638151; Page no: 494; REPORT TITLE: - “Pharmaceutical industry pulse”; AUTHOR: Scala, Stephen, et al; DATE: 01/13/2020
PF-06480605 / PfizerA Study to Evaluate the Efficacy and Safety of PF-06480605 in Adult Participants With Moderate to Severe Ulcerative Colitis (clinicaltrials.gov) - Jan 23, 2020 - P2b; N=240; Recruiting; Sponsor: Pfizer; Not yet recruiting --> Recruiting
Xeljanz (tofacitinib) / PfizerXeljanz sales estimate: $2.275B in 2019; Xeljanz sales projection: $2.645B in 2020 and $4.405B in 2025 (Cowen & Co) - Jan 22, 2020 - A subscription to Thomson ONE is required to gain full access to report 68638151; Page no: 670; REPORT TITLE: - “Pharmaceutical industry pulse”; AUTHOR: Scala, Stephen, et al; DATE: 01/13/2020
Skyrizi (risankizumab) / AbbVie, Boehringer IngelheimSkyrizi sales estimate: $275M in 2019; Skyrizi sales projection: $850M in 2020 and $3.4B in 2025 (Cowen & Co) - Jan 21, 2020 - A subscription to Thomson ONE is required to gain full access to report 68638151; Page no: 72; REPORT TITLE: "Pharmaceutical industry pulse"; AUTHOR: Scala, Stephen, et al; DATE: 01/13/2020
Humira (adalimumab) / Eisai, AbbVieHumira sales estimate: $19.125B in 2019; Humira sales projection: $18.955B (guidance: $21B) in 2020, $14B in 2023, $10B in 2024 and $5.5B in 2025 (Cowen & Co) - Jan 21, 2020 - A subscription to Thomson ONE is required to gain full access to report 68638151; Page no: 35, 52; REPORT TITLE: "Pharmaceutical industry pulse"; AUTHOR: Scala, Stephen, et al; DATE: 01/13/2020
Simponi (golimumab) / Merck (MSD), Mitsubishi Tanabe, J&JSimponi ex-US sales estimate: $835M in 2019; Simponi ex-US sales projection: $795M in 2020 and $550M in 2025 (Cowen & Co) - Jan 21, 2020 - A subscription to Thomson ONE is required to gain full access to report 68638151; Page no: 494; REPORT TITLE: - “Pharmaceutical industry pulse”; AUTHOR: Scala, Stephen, et al; DATE: 01/13/2020
